The apitegromab group lost about the same total weight as the placebo group, but the composition of that weight loss was meaningfully different: 85% of the lost weight was fat in the apitegromab group, compared to 70% fat in the placebo group
The 'LR3' designation refers to a 13-amino-acid N-terminal extension and a glutamic acid substitution at position 3, which together reduce binding affinity for IGF-binding proteins (IGFBPs) by approximately 100-fold
When youre losing weight, the goal isnt simply to eat less, but rather, to lose body fat while maintaining muscle tone, strength, energy, and long-term metabolic health
They may also affect: Insulin sensitivity Fat distribution Muscle mass Appetite and satiety signals Sleep quality Stress response As estrogen declines, the body tends to store more visceral fat even if caloric intake remains the same